Search

Your search keyword '"Breedveld F"' showing total 12 results
Start Over Author "Breedveld F" Language undetermined
12 results on '"Breedveld F"'

1. Tenidap: A Novel Cytokine-modulating Antirheumatic Drug for the Treatment of Rheumatoid Arthritis

Author

Breedveld F

Subjects
Adult, Male, Indoles, medicine.medical_treatment, Immunology, Pharmacology, Bone resorption, Arthritis, Rheumatoid, Rheumatology, Animals, Humans, Immunology and Allergy, Medicine, Serum amyloid A, Aged, Aged, 80 and over, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Acute-phase protein, General Medicine, Middle Aged, medicine.disease, Oxindoles, Rats, Antirheumatic Agents, Disease Models, Animal, Treatment Outcome, Cytokine, Clinical Trials, Phase III as Topic, Consumer Product Safety, Rheumatoid arthritis, Monocyte differentiation, Cytokines, Female, Tenidap, business, Acute-Phase Proteins, medicine.drug
Abstract

Tenidap is a novel, once-daily, cytokine modulating antirheumatic drug indicated for the treatment of rheumatoid arthritis (RA). In vitro, tenidap significantly inhibits the production of the pro-inflammatory cytokines, interleukin-1, interleukin-6 and tumour necrosis factor in human cell lines, and inhibits cytokine-mediated processes such as cartilage degradation, bone resorption, metalloprotease synthesis, endothelial cell adhesion and monocyte differentiation. Tenidap also inhibits cyclo-oxygenase. In RA patients, tenidap 120 mg/day is clinically equivalent to the combination of disease-modifying antirheumatic agents plus non-steroidal anti-inflammatory drugs (NSAIDs) and significantly more effective than NSAIDs. Tenidap also produces rapid, profound and sustained reductions in the serum levels of the acute phase proteins, C-reactive protein and serum amyloid A, an effect suggestive of disease modifying properties. In addition, tenidap reduces circulating levels of IL-6 in RA patients. Tenidap is well tolerated.

Published
1994

2. Minimal clinically important difference module: summary, recommendations, and research agenda

Author

Wells, G., Anderson, J., Beaton, D., Bellamy, N., Boers, M., Bombardier, C., Breedveld, F., Carr, A., Cranney, A., Dougados, M., Felson, D., Kirwan, J., Schiff, M., Shea, B., Simon, L., Smolen, J., Strand, V., Tugwell, P., Riel, P., and Vivian Welch

Subjects
Pathogenese en behandeling [Chronische arthritis], Pathogenesis and treatment [Chronic arthritis]
Abstract

Item does not contain fulltext

Published
2001

3. Dutch dispatch

Author

Cats, A and Breedveld, F C

Subjects
Universities, Rheumatology, Immunology, Humans, Immunology and Allergy, General Biochemistry, Genetics and Molecular Biology, Research Article, Netherlands
Published
1990

5. EULAR recommendations for the managements of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 Update,Odporúčania EULAR pre manažment reumatoidnej artritídy syntetickými a biologickými ochorenie modifikujúcimi antireumatickými liekmi: Aktualizácia 2013

Author

Smolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., Ramiro, S., Winthrop, K., Wit, M., Aletaha, D., Betteridge, N., Bijlsma, J. W. J., Boers, M., Buttgereit, F., Combe, B., Cutolo, M., Damjanov, N., Hazes, J. M. W., Kouloumas, M., Kvien, T. K., Mariette, X., Karel Pavelka, Riel, P. L. C. M., Rubbert-Roth, A., Scholte-Voshaar, M., Scott, D. L., Sokka-Isler, T., Wong, J. B., and Heijde, D.

7. Evidence for the Role of an Altered Redox State in Hyporesponsiveness of Synovial T Cells in Rheumatoid Arthritis

Author

Madelon Maurice, Nakamura, H., Voort, E. A. M., Vliet, A. I., Staal, F. J. T., Tak, P. -P, Breedveld, F. C., and Verweij, C. L.

Subjects
Immunology, Immunology and Allergy
Abstract

In rheumatoid arthritis (RA), T cells isolated from the synovial fluid (SF) show impaired responses to mitogenic stimulation compared with T cells from the peripheral blood (PB). Here it is reported that hyporesponsiveness of SF T cells correlated with a significant decrease in the levels of the intracellular redox-regulating agent glutathione (GSH). GSH was decreased in both CD4+ (p = 0.0022) and CD8+ (p = 0.0010) SF T cell subsets compared with PB CD4+ and CD8+ T cells in RA patients. Levels of thioredoxin (TRX), another key redox mediator, previously found to be secreted under conditions of oxidative stress, were found to be significantly increased in SF compared with plasma samples of RA patients (p = 0.005). Increased levels of TRX in the SF of inflamed joints was found to be associated with RA when compared with other arthritides (p = 0.007). Restoration of GSH levels in SF T cells with N-acetyl-L-cysteine (NAC), enhanced mitogenic induced proliferative responses and IL-2 production. Collectively, these data impute an important role to an altered redox state in the hyporesponsiveness of joint T cells in patients with RA.

10. The Eular recommendations for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs,Eular odporúčania pre manažment reumatoidnej artritidy so syntetickými a biologickými ochorenie modifikujúcimi antireumatickými liekmi

Author

Smolen, J. S., Landewé, R., Breedveld, F. C., Dougados, M., Emery, P., Gaujoux-Viala, C., Gorter, S., Knevel, R., Nam, J., Schoels, M., Aletaha, D., Buch, M., Gossec, L., Huizinga, T., Bijlsma, J. W. J. W., Burmester, G., Combe, B., Cutolo, M., Gabay, C., Gomez-Reino, J., Kouloumas, M., Kvien, T. K., Martin-Mola, E., Mcinnes, I., Karel Pavelka, Riel, P., Scholte, M., Scott, D. L., Sokka, T., Valesini, G., Vollenhoven, R., Winthrop, K. L., Wong, J., Zink, A., and Heijde, D.

Catalog

Books, media, physical & digital resources
See catalog results